Galantamine
RAZADYNE
What it isAcetylcholinesterase inhibitor and neuronal nicotinic-receptor modulator; symptomatic treatment of Alzheimer dementia.
Why it mattersUnique among cholinesterase inhibitors in positively modulating neuronal nicotinic receptors, though outcomes resemble its peers.
What it changesBradycardia, syncope, and GI intolerance end trials; renal or hepatic impairment limits use.
FDA-approved for
- Alzheimer dementia (2001)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Alzheimer's dementia (mild–moderate) | Adults | 4 mg BID | 8–12 mg BID (16–24 mg/day) | 24 mg/day (recommended range 16–24 mg/day) |
Titration Increase to next dose after a minimum of 4 weeks at the prior dose
Renal Do not exceed 16 mg/day for CrCl 9–59 mL/min; do not use if CrCl <9 mL/min
Hepatic Do not exceed 16 mg/day in moderate impairment; do not use in severe impairment
Instructions
- Take with food; ensure adequate fluid intake
- If therapy interrupted ≥3 days, restart at the lowest dose and re-titrate
Cautions
- Serious skin reactions (SJS, AGEP) — discontinue at first rash
- Bradycardia and AV block (vagotonic effects)
- GI bleeding — risk in ulcer-prone patients
- Bladder outflow obstruction
- Respiratory events in severe asthma/COPD
- Exaggerated neuromuscular blockade during anesthesia
Adverse reactions
- Nausea
- Vomiting
- Diarrhea
- Dizziness
- Headache
- Decreased appetite
Pregnancy No adequate human data; developmental toxicity in animals at clinical doses
Lactation Undefined
NO BOXED WARNINGS
Principal riskBradycardia and GI intolerance
Cost, est. cash$10–$500/month
Generic entry2008
Classes and tags
Clinical profile
Legacy pregnancy categoryB
Defining liabilityBradycardia, syncope or GI effects for symptomatic drugs; anti-amyloid agents add edema/hemorrhage risk.
Mechanism of action: Galantamine ballicule
Open Galantamine in the interactive console ↗
Memory aids: mascots and interaction avatars
baby blue theme → muscarinic
